Sutro Biopharma
STRO
43 hedge funds and large institutions have $97.3M invested in Sutro Biopharma in 2018 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 10 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
34% more funds holding
Funds holding: 32 → 43 (+11)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.5% less ownership
Funds ownership: 5.24% → 4.75% (-0.5%)
29% less capital invested
Capital invested by funds: $137M → $97.3M (-$40.2M)
Top Buyers
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 3 |
BlackRock
New York
|
+$843K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$776K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$611K |
Top Sellers
| 1 |
CI
Cowen Inc
New York
|
-$6.26M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.25M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.67M |
| 4 |
Millennium Management
New York
|
-$1.15M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$715K |
STRO Hedge Fund Activity: Q4 2018 in Review
43 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2018, worth a combined $97.3M — down 29% from $137M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new STRO positions and 10 closed out — a net gain of 12 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $1.6M. The largest seller was Cowen Inc, exiting entirely with an estimated $6.26M sold.
- 43 institutional investors held Sutro Biopharma (STRO) as of Q4 2018, up from 32 in Q3 2018.
- Funds reported $97.3M of Sutro Biopharma stock for Q4 2018, down 29% quarter-over-quarter.
- 22 funds opened new Sutro Biopharma positions in Q4 2018 and 10 closed out, a net change of +12 holders.
- The largest Sutro Biopharma buyer in Q4 2018 was Sphera Funds Management, an estimated $1.6M added.
- The largest Sutro Biopharma seller in Q4 2018 was Cowen Inc, an estimated $6.26M sold.
Based on aggregated 13F filings for Q4 2018.